Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016 — Aviv Ladanie (2020) | RDL Network
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
Article 2020 en
Authors
AL
Aviv Ladanie
AS
Andreas M. Schmitt
BS
Benjamin Speich
Abstract
1 min read
In this study, data available at the time of FDA drug approval indicated that novel cancer therapies were associated with substantial tumor responses but with prolonging median overall survival by only 2.40 months. Approval data from 17 years of clinical trials suggested that patients and clinicians typically had limited information available regarding the benefits of novel cancer treatments at market entry.
Discussion(0)
No comments yet. Be the first to comment.